FI110162B - Menetelmä farmaseuttisten inhalaatiokoostumusten valmistamiseksi - Google Patents

Menetelmä farmaseuttisten inhalaatiokoostumusten valmistamiseksi Download PDF

Info

Publication number
FI110162B
FI110162B FI944123A FI944123A FI110162B FI 110162 B FI110162 B FI 110162B FI 944123 A FI944123 A FI 944123A FI 944123 A FI944123 A FI 944123A FI 110162 B FI110162 B FI 110162B
Authority
FI
Finland
Prior art keywords
range
polysaccharide
composition
inhalation
separate particles
Prior art date
Application number
FI944123A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI944123A0 (fi
FI944123A (fi
Inventor
Paul Wright
Lewis James Baskeyfield
Graham Frederick Jay
Original Assignee
Fisons Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929205183A external-priority patent/GB9205183D0/en
Priority claimed from GB929205738A external-priority patent/GB9205738D0/en
Priority claimed from GB929205739A external-priority patent/GB9205739D0/en
Application filed by Fisons Plc filed Critical Fisons Plc
Publication of FI944123A0 publication Critical patent/FI944123A0/fi
Publication of FI944123A publication Critical patent/FI944123A/fi
Application granted granted Critical
Publication of FI110162B publication Critical patent/FI110162B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
FI944123A 1992-03-10 1994-09-08 Menetelmä farmaseuttisten inhalaatiokoostumusten valmistamiseksi FI110162B (fi)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB9205183 1992-03-10
GB929205183A GB9205183D0 (en) 1992-03-10 1992-03-10 Formulation
GB9205738 1992-03-17
GB929205738A GB9205738D0 (en) 1992-03-17 1992-03-17 Formulations
GB929205739A GB9205739D0 (en) 1992-03-17 1992-03-17 Formulations
GB9205739 1992-03-17
PCT/GB1993/000503 WO1993017663A1 (en) 1992-03-10 1993-03-10 Pharmaceutical inhalation compositions
GB9300503 1993-03-10

Publications (3)

Publication Number Publication Date
FI944123A0 FI944123A0 (fi) 1994-09-08
FI944123A FI944123A (fi) 1994-09-08
FI110162B true FI110162B (fi) 2002-12-13

Family

ID=27266086

Family Applications (1)

Application Number Title Priority Date Filing Date
FI944123A FI110162B (fi) 1992-03-10 1994-09-08 Menetelmä farmaseuttisten inhalaatiokoostumusten valmistamiseksi

Country Status (12)

Country Link
US (1) US5607662A (de)
EP (1) EP0630230B1 (de)
JP (1) JP2736168B2 (de)
AT (1) ATE145819T1 (de)
CA (1) CA2131285C (de)
DE (1) DE69306379T2 (de)
DK (1) DK0630230T3 (de)
ES (1) ES2099428T3 (de)
FI (1) FI110162B (de)
GR (1) GR3022527T3 (de)
NO (1) NO307203B1 (de)
WO (1) WO1993017663A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US6413496B1 (en) 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
US6349719B2 (en) 1997-02-24 2002-02-26 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
US6192882B1 (en) * 1997-02-24 2001-02-27 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US6197280B1 (en) 1997-09-09 2001-03-06 Bioglan Laboratories Limited Pharmaceutical compositions and devices for their administration
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
TR200001596T2 (tr) * 1997-12-03 2000-12-21 Fujisawa Pharmaceutical Co., Ltd. Yumuşak hap ilaç ve bunun üretim usulü
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
AU7685200A (en) * 1999-10-12 2001-04-23 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0010709D0 (en) * 2000-05-03 2000-06-28 Vectura Ltd Powders for use a in dry powder inhaler
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
EP1458360B1 (de) 2001-12-19 2011-05-11 Novartis AG Pulmonale verabreichung von aminoglykosiden
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
JP2006087815A (ja) * 2004-09-27 2006-04-06 Canon Inc 噴霧方法および該方法に基づく噴霧装置
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) * 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
JP2011503073A (ja) 2007-11-13 2011-01-27 メリテイジ ファーマ，インク． コルチコステロイド組成物
WO2010144865A2 (en) * 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
JP2020510002A (ja) * 2017-03-07 2020-04-02 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 吸入可能なニコチン製剤、およびその作製および使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201685B (en) * 1987-04-23 1990-12-28 Chinoin Gyogyszer Es Vegyeszet For producing pharmaceutical compositions for inhalation and compositions for scenting air containing volatile active component in cyclodextrine inclusion, and air-scenting composition
GB8820398D0 (en) * 1988-08-27 1988-09-28 Fisons Plc Pharmaceutical formulation
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers

Also Published As

Publication number Publication date
NO943241L (no) 1994-09-01
US5607662A (en) 1997-03-04
CA2131285A1 (en) 1993-09-16
FI944123A0 (fi) 1994-09-08
NO307203B1 (no) 2000-02-28
NO943241D0 (no) 1994-09-01
JP2736168B2 (ja) 1998-04-02
EP0630230B1 (de) 1996-12-04
GR3022527T3 (en) 1997-05-31
JPH07504432A (ja) 1995-05-18
ATE145819T1 (de) 1996-12-15
EP0630230A1 (de) 1994-12-28
WO1993017663A1 (en) 1993-09-16
DK0630230T3 (da) 1997-06-02
FI944123A (fi) 1994-09-08
DE69306379T2 (de) 1997-06-12
DE69306379D1 (de) 1997-01-16
ES2099428T3 (es) 1997-05-16
CA2131285C (en) 2004-06-29

Similar Documents

Publication Publication Date Title
FI110162B (fi) Menetelmä farmaseuttisten inhalaatiokoostumusten valmistamiseksi
ES2213180T3 (es) Polvos y su uso en inhaladores de polvo seco.
AU635616B2 (en) Aerosol carriers
US7022311B1 (en) Powdery inhalational preparations and process for producing the same
US20060057073A1 (en) Wet granulation process
HRP20000666A2 (en) Pulmonary and nasal delivery of raloxifene
WO1999027911A1 (fr) Medicament en pastilles souples et procede de fabrication
US20130064870A1 (en) Dry powder inhalation composition
AU2013275113A1 (en) Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
US20170172925A1 (en) Process for preparing a medicament
JP2004534813A (ja) 安定な粉末吸入投与組成物
CA2670155C (en) Stable powder formulation containing an anticholinergic agent
JPH11106339A (ja) Ｃｒ２０３９を含有する吸入用医薬組成物
Vanderbist et al. Optimization of a dry powder inhaler formulation of nacystelyn, a new mucoactive agent
KR20190027844A (ko) 흡입용 의약 조성물
EP1115380B2 (de) Micronisierte pharmazeutische zusammensetzungen
US20130115282A1 (en) Polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof
JP2022139708A (ja) 吸入用乾燥粉末医薬組成物
MXPA00009704A (en) Pulmonary and nasal delivery of raloxifene